Overview
The FTC and DOJ’s proposed revised merger guidelines signal the Biden administration’s continued aggressive antitrust enforcement stance even as healthcare industry participants continue to seek to overcome the effects of inflation, a difficult capital market cycle and overall challenging operating environment.
Join McDermott Health Antitrust partners Ashley Fischer and Stephen Wu, and Kaufman Hall M&A practice leader Anu Singh for a deep dive into the implications of the FTC and DOJ’s revised merger guidelines for healthcare industry M&A, including:
- How the revised merger guidelines differ from the current guidelines
- What they mean for healthcare organizations and those doing deals in the healthcare space
- What organizations can do to navigate a more complex antitrust environment for future M&A transactions in the health industry
